Tight junction proteins

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Retrieved on: 
Monday, September 26, 2022
Disability, Retina, Therapy, Hepatitis, Probability, Traffic barrier, ECS, Volkmann's contracture, Degenerative disease, Human, COVID-19, Retinopathy, Homeostasis, Inflammatory bowel disease, Diabetic retinopathy, Senior, Intravitreal injection, Forward-looking statement, VEGF, Severe cognitive impairment, Regeneration, Diabetes, U.S. Securities and Exchange Commission, Cornea, Pancreas, Disease, DR, WNT, FZD4, Soft tissue injury, Annual report, Liver, Coronavirus, Technology, Tissue, Lung, Eye, Research, Security (finance), GLOBE, Skin, Gene expression, Translational Vision Science & Technology, LRP5, Tight junction proteins, Infection, Lists of disasters, Medical imaging, Pharmaceutical industry, Dentistry, Biology

Diabetic retinopathy is a microvascular complication of diabetes and a serious public health problem as it is a major cause of vision loss and disability in the middle-aged population.

Key Points: 
  • Diabetic retinopathy is a microvascular complication of diabetes and a serious public health problem as it is a major cause of vision loss and disability in the middle-aged population.
  • The pathogenesis of DR leads to vascular leakage, which causes diabetic macular edema, and capillary occlusion causing retinal ischemia.
  • In a preclinical oxygen-induced retinopathy model, intravitreal injections of SZN-413 significantly reduced avascular area size compared to the positive control, aflibercept.
  • These results suggest that this modulation of FZD4 signaling may address important pathologic vascular characteristics of diabetic retinopathy, said Wen-Chen Yeh, M.D., Ph.D., Chief Scientific Officer at Surrozen.

Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

Retrieved on: 
Thursday, September 15, 2022
Therapy, Degenerative disease, Path integral molecular dynamics, Severe acute respiratory syndrome coronavirus 2, Monoclonal antibody, Antibody, Gene, Industry, Diabetes, Patient, Cancer, CEO, Ion, Technology, Doctor of Philosophy, Lymphatic system, Lung, Tumor microenvironment, Research, G protein-coupled receptor, Tight junction proteins, CAR, Fine chemical, Medical imaging, Vaccine

PHILADELPHIA, Sept. 15, 2022 /PRNewswire/ -- Integral Molecular, the industry leader in discovering antibodies against complex membrane protein targets, has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular's Claudin 18.2 (CLDN18.2) MAbs.

Key Points: 
  • PHILADELPHIA, Sept. 15, 2022 /PRNewswire/ -- Integral Molecular, the industry leader in discovering antibodies against complex membrane protein targets, has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular's Claudin 18.2 (CLDN18.2) MAbs.
  • "We look forward to the synergy of our high-specificity MAbs with CARTEXELL's CAR-T cell therapy technology to bring new therapies to patients."
  • Integral Molecular ( integralmolecular.com ) is the industry leader in developing innovative technologies to advance the discovery of therapeutics against challenging protein targets.
  • Cartexell will continue to grow into a global biotech company in the field of gene and cell therapy.

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies Bundle Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Antibody, Safety, CDH17, Metastasis, CAR, Tight junction proteins, CLDN6, Drug discovery, Ligand, Industry, Trial of the century, Embryonic development, B-cell maturation antigen, Population, Glycoprotein, EC, BCMA, Cancer, Cell adhesion, B cell, Tissue, ROR1, Testicle, Receptor, Cadherin, Nephron, Probability, Patient, Cell, CD138, Skin, Competitive landscape, GPRC5D, Immunotherapy, Perspiration, Protein, Multiple myeloma, Organogenesis, CLDN9, Human, Adult, Dietary supplement, Vaccine, Retail, Medical imaging, Healthcare, Pharmaceutical industry, Risk management, Sales

The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
  • The tetraspan membrane protein is a member of the claudin family of tight junction proteins.
  • The transmembrane protein CLDN6 is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.

Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 20, 2022
Health, Pharmaceutical, Target, Antibody, Cancer, CAR, Cell, Drug discovery, CLDN6, CLDN9, Protein, Tissue, Adult, Tight junction proteins, Vaccine, Medical imaging, Pharmaceutical industry

The "Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.
  • The tetraspan membrane protein is a member of the claudin family of tight junction proteins.
  • Despite the technical challenge, novel cellular and humoral CLDN6-targeted drug modalities have emerged and the first product candidates entered clinical development.
  • The facts that preliminary clinical experience shows high anti-tumor activity of the first drug candidate and that the competitive field still is limited, make claudin 6 an exceptionally attractive target for drug discovery and development.